2 559

Cited 0 times in

Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.

DC Field Value Language
dc.contributor.author김기열-
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author박찬희-
dc.contributor.author신상준-
dc.contributor.author안중배-
dc.contributor.author임선민-
dc.contributor.author정현철-
dc.date.accessioned2014-12-18T09:14:47Z-
dc.date.available2014-12-18T09:14:47Z-
dc.date.issued2013-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87808-
dc.description.abstractBACKGROUND/AIM: To investigate mechanisms of discrepancy in response to a MEK/ERK inhibitor, U0126, in KRAS- and BRAF-mutant colorectal cancer cells. MATERIALS AND METHODS: Multiparametric flow cytometry was performed on two colon cancer cell lines, HCT116 and HT29. Cells were treated with U0126, and phospho-specific antibodies were used to monitor ERK signaling. RESULTS: HCT116 and HT29 cells were treated with increasing amounts of U0126. The western blot analysis revealed that by increasing the amount of U0126 resulted in inhibition of phospho-ERK, in HCT116 and to a lesser degree in HT29 cells. Microarray profiling identified CYP1A1 and 1A2 overexpression in HT29 cells and that inhibition of CYP1A1 with α-naphthoflavone and furanfylline restored sensitivity to U0126 in HT29 cells. CONCLUSION: Combination of a CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF-mutant colon cancer cells.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfANTICANCER RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHBenzoflavones/pharmacology-
dc.subject.MESHButadienes/pharmacology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Proliferation/drug effects-
dc.subject.MESHColonic Neoplasms/drug therapy*-
dc.subject.MESHColonic Neoplasms/genetics-
dc.subject.MESHCytochrome P-450 CYP1A1/antagonists & inhibitors*-
dc.subject.MESHCytochrome P-450 CYP1A1/metabolism-
dc.subject.MESHCytochrome P-450 CYP1A2/metabolism-
dc.subject.MESHEnzyme Inhibitors/pharmacology-
dc.subject.MESHExtracellular Signal-Regulated MAP Kinases/antagonists & inhibitors*-
dc.subject.MESHHumans-
dc.subject.MESHMAP Kinase Signaling System/drug effects-
dc.subject.MESHNitriles/pharmacology-
dc.subject.MESHProto-Oncogene Proteins B-raf/antagonists & inhibitors*-
dc.titleCombination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSUN MIN LIM-
dc.contributor.googleauthorJEE WON HWANG-
dc.contributor.googleauthorJOONG BAE AHN-
dc.contributor.googleauthorSOO KYUNG BAE-
dc.contributor.googleauthorCHAN HEE PARK-
dc.contributor.googleauthorKI-YEOL KIM-
dc.contributor.googleauthorSUN YOUNG RHA-
dc.contributor.googleauthorHYUN CHEOL CHUNG-
dc.contributor.googleauthorJAE KYUNG ROH-
dc.contributor.googleauthorSANG JOON SHIN-
dc.identifier.doi23749901-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00337-
dc.contributor.localIdA01290-
dc.contributor.localIdA01712-
dc.contributor.localIdA02105-
dc.contributor.localIdA02262-
dc.contributor.localIdA03369-
dc.contributor.localIdA03773-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00188-
dc.identifier.eissn1791-7530-
dc.identifier.pmid23749901-
dc.identifier.urlhttp://ar.iiarjournals.org/content/33/6/2499.long-
dc.subject.keywordCYP inhibitor-
dc.subject.keywordCell signaling-
dc.subject.keywordERK-
dc.subject.keywordHCT116-
dc.subject.keywordHT29-
dc.subject.keywordMEK/ERK inhibitor-
dc.subject.keywordU0126-
dc.subject.keywordcolorectal cancer-
dc.contributor.alternativeNameKim, Ki Yeol-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNamePark, Chan Hee-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorKim, Ki Yeol-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorPark, Chan Hee-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.contributor.affiliatedAuthorLim, Sun Min-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume33-
dc.citation.number6-
dc.citation.startPage2499-
dc.citation.endPage2508-
dc.identifier.bibliographicCitationANTICANCER RESEARCH, Vol.33(6) : 2499-2508, 2013-
dc.identifier.rimsid32283-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
2. College of Dentistry (치과대학) > Others (기타) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.